Uriach Corporation

Group of several companies: Corporation E. Uriach S.A. J, Uriach & Cia S.A., Biohorn S.A., Ulriach OTC S.L., Urquima S.A., Dimportex S.A., Parmagenus S.A.
Production Plant of Uriach: generic medicines, to which the high quality standards of the GMP are applied, are produced.
URIACH Corporation is present in forty countries, either through licence agreement of its research products, raw materials manufacturated by URQUIMA or trough the distribution of its finished products. URIACH molecules are marketed in fifty countries and are in the process of being registered in seventy other countries.The following are worth being mentioned: TRIFLUSAL Blood platelet antiaggregant licensed in thirty countries and marketed in 15 of such. FLUTRIMAZOL Topical fungicide with dermal presentations, licensed in over seventy countries. This product is currently in the phase of being registered in all of them, and therefore it is expected that it will be marketed in about 3 o 4 years. RUPATADINA Antihistaminic drug and PAF-antagonist in development phase.

Activity:

- Manufacturing

Product / Technology type(s) covered:

- API / chemicals
- Generics
- FP (finished products)
- OTC (over the counter drugs)
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)

Therapeutic targets:

Markets Covered

a. HeadQuarter: Spain

b. Continent(s) active: Europe , Central/South America , Africa , Asia

c. Countries active: Distibutors and licensees

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:
152000000	200	Euro

Year founded: 1858